MTAP deletion is rapidly emerging as a clinically actionable biomarker across multiple tumor types and is often associated with poor prognosis, creating new therapeutic opportunities while also exposing critical challenges in accurately detecting complex biomarkers for precision oncology trials. In Europe, limitations in testing capabilities and regulatory alignment continue to delay clinical trial enrolment and therapeutic process.
This webinar, delivered by SOPHiA GENETICS in collaboration with ARC Regulatory, will explore how comprehensive AI-driven genomic profiling, supported by robust assay implementation and workflow validation, can accelerate clinical trial assay development, reducing regulatory risk and enabling faster, more accurate identification of MTAP-deleted patients, ultimately broadening and expediting clinical trial recruitment across Europe.
Key Highlights
- Gain a clear understanding of MTAP deletion’s clinical relevance as a predictive biomarker, and see how current testing limitations can affect patient identification, cohort quality and overall trial design
- Explore how an agile, modular comprehensive genomic profiling strategy supports tailored biomarker coverage and allows seamless integration of RNA and HRD analysis, strengthening confidence in the accuracy and completeness of biomarker detection
- Learn how more reliable and scalable MTAP detection enables earlier identification of eligible patients, helping biopharma teams to accelerate and optimise clinical trial enrolment across Europe
- Understand how integrated assay implementation and workflow validation streamline clinical trial assay development, supporting smoother navigation of complex regulatory requirements to reduce risk
Why Attend?
- Stay ahead of fast-moving biomarker strategies that directly influence trial feasibility, patient selection, and future precision oncology programmes
- Gain practical guidance for navigating European testing and regulatory barriers, helping you reduce delays and remove enrolment bottlenecks
- Learn concrete approaches to shortening recruitment timelines, improving predictability and confidence in study delivery
- Understand how advances in AI-enabled genomic technologies can strengthen patient identification workflows
- Engage with experts during the live Q&A to get tailored, real-world insights that you can apply immediately to your biomarker-driven trials
If you are involved in Biomarkers, Precision Oncology, Assay Development or Clinical Development, join this webinar to accelerate and optimise your European precision oncology trial strategy.
Webinar Leaders
Julie Clark
Senior Specialist – Regulatory Affairs, ARC
Lina Li
Product Marketing Director – Application, SOPHiA GENETICS
Sofia Lima
BioPharma Marketing Manager, SOPHiA GENETICS
You May Also Be Interested In…
Learn More About Autoimmune
- The Most Comprehensive Way to Search the Autoimmune Drug Development Landscape: Unique search ontologies based on Autoimmune drug and trial characteristics
- Market Leading Approach to Autoimmune Preclinical & Clinical Data Curation: Manual curation of key Autoimmune research and development data points by Autoimmune research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Autoimmune company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
